Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

Slides:

Advertisements

Similar presentations

Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.

Advertisements

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.

NSAIDs 1 st line of therapy in the medical management of RA.

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,

Methotrexate Indications and Approaches

Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

Treatment of Vasculitis: immunesuppressives and biologics

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.

Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.

Therapeutic algorithms for Crohn’s disease: Where are we in 2012?

Rheumatoid Arthritis Anila Malik GPVTS. Aims To cover the following: What is RA? Diagnostic criteria and clinical features Rheumatoid Factor Investigations.

Rituximab for the Treatment of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.

Arthritis Facts. Leading Causes of Disability Among U.S. Adults, 1999 Among U.S. Adults, 1999 Arthritis is the leading cause of disability in the United.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.

Arthritis Facts. Leading Causes of Disability Among U.S. Adults, 1999 Among U.S. Adults, 1999 Arthritis is the leading cause of disability in the United.

Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.

Biological Differentiation Part II Dubai, United Arab Emirates January 19th, 2009 Prof. Joachim R. Kalden Director emeritus Dept. of Internal Medicine.

Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.

BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.

Disease modified Anti-rheumatic drugs ( DMARD)

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2015 Comparison of (Your site name) results against the national results.

Early Administration of Azathioprine Versus Conventional Management of Crohn’s Disease : A Randomized Controlled Trial F1. Ja Won Koo JACQUES COSNES, ANNE.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2015 Comparison of (Your site name) results against the national results.

Failure of 2 standard DMARDs including MTX for 6 months DAS28 > 5.1 on 2 occasions 1 month apart TOLERANT MTX Choose most appropriate agent and if no clear.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2016 Comparison of (Your site name) results against the national results.

A NEW LOOK AT RA Interactive Hot Topics Series

Biological therapies audit 2016

Hypertension November 2016

Treatment Goal of treatment reduce inflammation and pain

My Treatment Approach to Rheumatoid Arthritis

LONG TERM DRUG-FREE CLINICAL-REMISSION IN PATIENTS WITH RA ON cDMARDs

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Diagnosing Rheumatoid Arthritis Early

My Treatment Approach to Rheumatoid Arthritis

Complicated Cases in Ulcerative Colitis

Clinical Updates in RA: New Developments and Insights From Washington

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B Hanauer, Carrie L Wagner,

WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in

Fernando Velayos, Uma Mahadevan

Biotherapeutics.

What's New in Therapeutic Options for Moderate to Severe RA?

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Infections and Biologic Therapy in Rheumatoid Arthritis

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Hypertension November 2016

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.

Independent baseline predictors of non-remission at 24 months of follow-up in the SWEFOT trial population. Independent baseline predictors of non-remission.

Nat. Rev. Rheumatol. doi: /nrrheum

Clinical response in patients with early and established RA at month 24. *p

Rheumatoid Arthritis.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Crohn’s Disease Biologic Pathway

Patient disposition after 2 years of treatment.

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS Trust

NICE Recommendations for Biologics in the treatment of R.A   TNF inhibitors are recommended as options for the treatment of adults who have active R.A. (DAS28 >5.1 x2) and have undergone a trial of at least 2 DMARDS (normally 6 months) including Methotrexate   TNF inhibitors should only be continued if there is an adequate response at 6 months (DAS28 improvement >1.2)   Pathway = NSAIDs > DMARDs > TNF inhibitors + Mtx

National population62,649,000 Estimated number of males30,842,103 Estimated number of females31,806,898 Incidence of RA in men in the UK per 100, Incidence of RA in women in the UK per 100,00054 Estimated number of men diagnosed with RA per year7,557 Estimated number of women diagnosed with RA per year 17,176 Estimated number of patients diagnosed with RA per year 24,733 Estimated number to start oral MTX per year (>44 yrs) 18,159 Rheumatoid Arthritis Patient Population

New R.A. Patients Starting a Biologic Estimated number of patients diagnosed with RA per year receiving oral MTX 18,159 Oral MTX failure rate21% Number of oral MTX failures3,813 Percentage of patients with stable baselines above DAS baseline >5.1 eligible for biologic therapy 1 76% Total number of new patients Mainman H et al. Clin Rheumatol 2010;29:

NICE Recommendations for Biologics in Crohns Disease   Infliximab or adalibumab are recommended as treatment options for adults with severe active Crohns whose disease has not responded or intolerant to conventional therapy (immunosuppressive and/or corticosteroid treatment)   Infliximab or adalibumab should be given as a planned course of treatment until treatment failure or until 12 months after start of treatment whichever is shorter. Then reassess.

Clinical Pathway Prednisolone Methylprednisolone or IV Hydrocortisone (5ASA if these are CI) Azathioprine or Mercaptopurine

Workshop Given what you now know consider possible options for the use of Infliximab biosimilar in your locality which could include (upto100%) switch, new patients only, or one speciality only Using the usage data estimate the potential financial impact of your model assuming a 30% price reduction on the current Branded Infliximab hospital price Consider what the barriers to change there may be in your locality What would be needed to overcome these barriers.